The ongoing LAURA trial (NCT03521154) is evaluating the efficacy of a third‐generation EGFR‐TKI, osimertinib, as maintenance treatment for patients with unresectable, EGFR‐mutant, stage III NSCLC who have not progressed following CRT treatment.29 Here, EGFR is linked to non-small cell lung carcinoma.